Real-World Evidence Demonstrates the Highest Response and Remission Rates Observed to Date for Deep BURLINGTON, Mass. and JERUSALEM, March 28, 2023…
atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living…
CHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced…
The Keswick Group is led by experienced pharmaceutical business development executive, Tony GoodmanCHARLOTTESVILLE, Va., March 21, 2023 (GLOBE NEWSWIRE) --…
Patient feedback from the standardized Brief Addiction Monitor (BAM) assessment demonstrates reductions in drug and alcohol usage, and other risk…
CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving…
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoingDisclosure of initial data from Phase 1 arm…
Results from Planned Interim Analysis Expected Fourth Quarter 2023 Approximately 21 Million Adults in U.S. Suffer From a Major Depressive…
Professor Kranzler is the Benjamin Rush Professor of Psychiatry and Director of the Center for Studies of Addiction at the…
BRYAN, Texas, March 14, 2023 (GLOBE NEWSWIRE) -- More Than Rehab is excited to announce that their Medical Director, Dr.…